Table 1.

Clinical Outcomes from Pivotal Trials in Patients with dMMR/MSI-H.

	KEYNOTE-177		CheckMate 142			KEYNOTE-164		KEYNOTE-016
Treatment line	1st		1st	≥ 2nd	≥ 2nd	≥ 2nd	≥ 3rd	≥ 3rd
Phase	III		II	II	II	II		II
Number of patients	153	154	45	74	119	63	61	10
Regimen	Pembro	Chemo	Nivo + Ipi*	Nivo	Nivo + Ipi**	Pembro	Pembro	Pembro
ORR	44%	33%	60%	31%	55%	33%	33%	40%
DCR	65%	75%	84%	69%	80%	57%	51%	90%
mPFS (months)	16.5	8.2	NR	14.3	NR	4.1	2.3	NR
12-month PFS rate	55%	37%	77%	50%	71%	41%		78% (at 20 weeks)
mOS (months)	-	-	NR	NR	NR	NR	31.4	NR
12-month OS rate	-	-	83%	73%	85%	76%	72%	-

Abbreviations: dMMR, deficient mismatch repair; MSI-H, microsatellite instability-high; Pembro, pembrolizumab; Nivo, nivolumab; Ipi, ipilimumab; Chemo, chemotherapy; ORR, overall response rate; DCR, disease control rate; PFS, progression-free survival, OS, overall survival; NR, not reached.

* Nivo 3 mg/kg biweekly + Ipi 1 mg/kg every 6 weeks

** Nivo 3 mg/kg + Ipi 1 mg/kg every 3 weeks (four doses) followed by Nivo 3 mg/kg biweekly